Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $554.61, for a total value of $5,268,795.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,468,914.93. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Up 1.6%

Shares of UTHR stock traded up $8.76 during trading hours on Thursday, hitting $555.91. 531,986 shares of the company were exchanged, compared to its average volume of 498,740. The firm has a market cap of $23.60 billion, a PE ratio of 20.52, a PEG ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm has a fifty day moving average of $559.06 and a 200 day moving average of $527.20.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $6.63 EPS. Analysts expect that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. Leuthold Group LLC raised its stake in United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after acquiring an additional 3,126 shares in the last quarter. UBS Group AG grew its stake in shares of United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares in the last quarter. Perpetual Ltd acquired a new position in shares of United Therapeutics during the fourth quarter valued at $1,059,000. SG Americas Securities LLC increased its holdings in shares of United Therapeutics by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock valued at $13,136,000 after purchasing an additional 12,663 shares during the period. Finally, Brookstone Capital Management raised its stake in shares of United Therapeutics by 25.4% during the fourth quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock valued at $3,227,000 after purchasing an additional 1,342 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on UTHR. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. HC Wainwright lifted their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. UBS Group boosted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Royal Bank Of Canada dropped their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.